Dr. McCluskey: Treatment Burden

OUR COLLEAGUE: Jessica D. McCluskey, MD — Atlanta, GA

"I wanted a treatment that was designed to treat patients for a longer time. When your patients ask, answer and act."
— Jessica D. McCluskey, MD

Above results are from a single case; results may vary.

Board-certified ophthalmologist and fellowship-trained retina specialist at Thomas Eye Group, a large multispecialty ophthalmology practice.

Academic affiliations:
  • Medical School at the University of Mississippi – received Awards in Excellence in the elds of ophthalmology and neurosurgery
  • Four-year ophthalmology residency at the University of Mississippi where she served as chief resident
  • Two-year retina fellowship at the University of Texas Southwestern Medical Center

Patient Profile 1
Sex: Female
Age: 73
Diagnosis: DME
Treated Eye: OS
Concomitant conditions:
  • High blood pressure
  • Hypercholesterolemia
  • Proliferative diabetic retinopathy with 2 panretinal photocoagulations
Treatment history:
2X Focal laser
8X Anti-VEGF
6X Corticosteroid

Reasons Dr. McCluskey chose ILUVIEN:
  • Patient history of monthly injections over the course of 6 years
  • Missed injections negatively impacted patient’s vision
  • Interested in an alternative to monthly injections

Retinal Thickness (µm)
Retinal Thickness
Best Corrected Visual Acuity (BCVA)
Best Corrected Visual Acuity
IOP: Intraocular Pressure
Intraocular Pressure

Patient Results
ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg:

Patient Outcome
  • Vision maintained over 1 year of follow-up, despite having DME for 6 years with 16 prior treatments
  • Good optical coherence tomography (OCT) reduction and maintenance
  • IOP stable
  • No further treatment was needed during the 15-month follow-up period
Selected OCT Scans
1. Data on File. Alimera Sciences, Inc.

"This patient received monthly DME injections for years and after the ILUVIEN injection, she has not had another injection in 16 months. That’s a huge success for my patient."
— Dr. McCluskey